Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
February 2014, Vol 5, No 1
February 2014, Vol 5, No 1
Rituximab Infusions Costlier When Given in the Hospital than in the Office Setting
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
>New Orleans, LA—More patients with diffuse large B-cell lymphoma (DLBCL) are receiving rituximab infusions in the hospital setting, incurring greater costs than those receiving infusions in the office or clinic, an examination of medical and pharmacy claims has shown.
Read Article
Physicians Must Consider the Financial Burden Associated with Allogeneic Transplants
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
New Orleans, LA—Recipients of allogeneic hematopoietic cell transplant are at high risk for financial burden, according to survey-based data collected by Nandita Khera, MD, MPH, a medical oncologist from the Blood and Marrow Transplant Program, Mayo Clinic Arizona, Phoenix, and colleagues.
Read Article
Decitabine More Cost-Effective than Conventional Induction in Older Patients with AML
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
New Orleans, LA—The use of decitabine (Dacogen) is more cost-effective than conventional induction therapy for patients aged >60 years with acute myeloid leukemia (AML), according to data from a recent economic analysis.
Read Article
Higher Copays for Imatinib Lead to Medication Nonadherence in Patients with CML
By
Neil Canavan
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
>Patients with chronic myeloid leukemia (CML) and high out-of-pocket (OOP) costs for treating their disease have a 70% chance of discontinuing treatment and a 42% chance of nonadherence to treatment compared with patients with lesser copays. These conclusions, which were recently published online (Dusetzina SB, et al.
J Clin Oncol
.
Read Article
1 in 5 US Clinical Trials Fails to Complete
By
Phoebe Starr
Genitourinary Cancers Symposium
February 2014, Vol 5, No 1
San Francisco, CA—The early termination of clinical trials is a tremendous waste of resources and can leave patients with cancer with no improved treatment options.
Read Article
Adding Radiation to Antiandrogen Hormone Therapy Extends Survival in Patients with High-Risk Prostate Cancer
By
Phoebe Starr
Genitourinary Cancers Symposium
February 2014, Vol 5, No 1
San Francisco, CA—Radiation added to hormone therapy with antiandrogens extended cancer-specific survival, as well as overall survival, when used as the primary treatment of patients with locally advanced or high-risk prostate cancer.
Read Article
Angiotensin System Inhibitors Extend Survival in Patients with Metastatic Renal-Cell Carcinoma
By
Phoebe Starr
Genitourinary Cancers Symposium
February 2014, Vol 5, No 1
San Francisco, CA—The use of angiotensin system inhibitors (ASIs) improved survival in patients with metastatic renal-cell carcinoma (mRCC) by 9 months, according to a retrospective pooled analysis of several clinical trials presented at the 2014 Genitourinary Cancers Symposium.
Read Article
Ibrutinib Approved for Chronic Lymphocytic Leukemia
By
Jayson Slotnik, JD, MPH
FDA Approvals, News & Updates
February 2014, Vol 5, No 1
The FDA approved a new indication for ibrutinib (Imbruvica; Pharmacyclics) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least 1therapy before.
Read Article
Dabrafenib Receives Breakthrough Therapy Designation for Lung Cancer
FDA Approvals, News & Updates
February 2014, Vol 5, No 1
Read Article
First Drug Combination Approved for Unresectable or Metastatic Melanoma
By
Jayson Slotnik, JD, MPH
FDA Approvals, News & Updates
February 2014, Vol 5, No 1
>The US Food and Drug Administration (FDA) approved the use of dabrafenib (Tafinlar; GlaxoSmithKline) plus trametinib (Mekinist; GlaxoSmithKline) as a new combination therapy for the treatment of patients with advanced melanoma that is unresectable or metastatic.
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma